Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 26 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Ribavirin may reduce use of clotting factors in hemophilia and Hep C

Findings based on case series in this week's issue of JAMA, show that ribavirin in combination with interferon, and possibly alone, may reduce the use of clotting factors in patients with hemophilia and chronic Hepatitis C.

News image

fiogf49gjkf04

Ribavirin has been used in combination with interferon-alfa to treat chronic Hepatitis C.

This combination therapy has been reported to be more effective than interferon monotherapy for eradicating Hepatitis C virus, including that occurring in patients with concomitant hemophilia.

Dr Takamatsu and colleagues from Japan aimed to assess the reduction in the use of clotting factors in Hepatitis C-positive patients with hemophilia treated with ribavirin and interferon.

The researchers treated 8 consecutive patients with hemophilia as outpatients for Hepatitis C infection with interferon and ribavirin between June 2002 and November 2003 at Nagoya University Hospital.

The team reported that all patients were men with a mean age of 45 years of which 6 patients had hemophilia A, and 2 had hemophilia B.

The mean use of clotting factors per month during treatment and after treatment lower than before treatment
JAMA

Hemophilia was severe in 3 patients, moderate in 2, and mild in 3 whilst 4 patients had been previously treated with interferon alfa-2b alone, but Hepatitis C virus had not been eradicated.

The investigators compared the average use of clotting factors from the 5 patients with moderate and severe hemophilia before, during, and after treatment.

Oral ribavirin was administered by the researchers at a dose of 600 mg/d for patients who weighed 60 kg or less and 800 mg/d for those who weighed more than 60 kg during 24 weeks.

The research team reduced the dose of ribavirin by 200 mg/d if the patient’s hemoglobin concentration decreased to below 10 g/dL due to hemolytic anemia induced by ribavirin; the hemoglobin level did not fall this low from any other causes.

In the 5 patients requiring clotting factor, the mean use of clotting factors per month for the 6 months prior to combination therapy was 3783 U/mo.

During therapy, the mean use of clotting factors per month was 1605 U/mo; and for the 6 months after therapy it was 1667 U/mo.

The researchers concluded that the mean use of clotting factors per month during treatment and after treatment lower than before treatment.

Dr Takamatsu concludes, “Based on this case series, ribavirin in combination with IFN, and possibly alone, may reduce the use of clotting factors in patients with hemophilia and chronic hepatitis C.”

“Further studies, including replication of these findings and clinical trials, would help to clarify the potential role of ribavirin in these patients.”

JAMA 2005: 293(10): 1190-1192
11 March 2005

Go to top of page Email this page Email this page to a colleague

 25 May 2018 
Colorectal cancer–specific mortality
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Post‐operative complications in elderly IBD
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us